MedTrace Logo

Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

NCT05529524 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2025-01-24

No results posted yet for this study

Summary

Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells. Bispecific antibodies (BsAb) are a promising treatment option which can induce long-term responses in refractory and relapsed B cell lymphoma patients. However, the factors determining the quality and duration of responses are poorly understood.

Conditions

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • The Lymphoma Academic Research Organisation

    lead OTHER

Principal Investigators

  • Camille Laurent, MD · Oncopole - Toulouse France

  • Karin Tarte, PhD · Micro-environnement et cancer (MICA) - Rennes France

  • Franck MORSCHHAUSER, MD · Centre Hospitalier Universitaire de Lille - Lille France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-07
Primary Completion
2024-01-22
Completion
2024-01-22

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05529524 on ClinicalTrials.gov